The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice

Blood Transfus. 2013 Jan;11(1):88-93. doi: 10.2450/2012.0176-11. Epub 2012 Jun 28.

Abstract

Background: Chronic transfusion therapy causes a progressive iron overload that damages many organs including the heart. Recent evidence suggests that L-type calcium channels play an important role in iron uptake by cardiomyocytes under conditions of iron overload. Given that beta-adrenergic stimulation significantly enhances L-type calcium current, we hypothesised that beta-adrenergic blocking drugs could reduce the deleterious effects of iron overload on the heart.

Methods: Iron overload was generated by intraperitoneal injections of iron dextran (1g/kg) administered once a week for 8 weeks in male C57bl/6 mice, while propranolol was administered in drinking water at the dose of 40 mg/kg/day. Cardiac function and ventricular remodelling were evaluated by echocardiography and histological methods.

Results: As compared to placebo, iron injection caused cardiac iron deposition. Surprisingly, despite iron overload, myocardial function and ventricular geometry in the iron-treated mice resulted unchanged as compared to those in the placebo-treated mice. Administration of propranolol increased cardiac performance in iron-overloaded mice. Specifically, as compared to the values in the iron-overloaded group, in iron-overloaded animals treated with propranolol left ventricular fractional shortening increased (from 31.6% to 44.2%, P =0.01) whereas left ventricular end-diastolic diameter decreased (from 4.1 ± 0.1 mm to 3.5 ± 0.1 mm, P =0.03). Propranolol did not alter cardiac systolic function or left ventricular sizes in the placebo group.

Conclusions: These results demonstrate that C57bl/6 mice are resistant to iron overload-induced myocardial injury and that treatment with propranolol is able to increase cardiac performance in iron-overloaded mice. However, since C57bl/6 mice were resistant to iron-induced injury, it remains to be evaluated further whether propranolol could prevent iron-overload cardiomyopathy.

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology*
  • Animals
  • Calcium Channels, L-Type / genetics
  • Calcium Channels, L-Type / metabolism*
  • Disease Models, Animal
  • Disease Resistance / drug effects*
  • Disease Resistance / genetics
  • Hematinics / adverse effects
  • Hematinics / pharmacology
  • Iron / metabolism*
  • Iron Overload / chemically induced
  • Iron Overload / genetics
  • Iron Overload / metabolism*
  • Iron Overload / pathology
  • Iron Overload / physiopathology*
  • Iron-Dextran Complex / adverse effects
  • Iron-Dextran Complex / pharmacology
  • Male
  • Mice
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Propranolol / metabolism*
  • Species Specificity

Substances

  • Adrenergic beta-Antagonists
  • Calcium Channels, L-Type
  • Hematinics
  • Iron-Dextran Complex
  • Propranolol
  • Iron